Freenome
Freenome to Lay off 20 Percent of Workforce
The cancer early detection firm disclosed the layoffs in a post on LinkedIn, stating that they are necessary to its realignment of strategic priorities.
Top Five Articles on 360Dx Last Week: FDA Warns Beckman Coulter; QuidelOrtho FDA Withdrawal; More
Last week, readers were most interested in a story about FDA warning Beckman Coulter about its manufacturing site for its DXl 9000 immunoassay analyzer.
Investors React to Initial Data on Freenome's Blood-Based Colon Cancer Detection Test
The company's trial results fell short of what some investors had predicted, easing competition concerns for both Guardant Health and Exact Sciences.
Freenome Raises $254M From Roche, Other Investors to Advance Cancer Early Detection Tests
The new funding will allow the firm to further develop its single- and multi-cancer early cancer detection tests that run on its multiomics platform.
Freenome Launches Prospective Study for Blood-Based Lung Cancer Screening Test
The PROACT LUNG observational trial will recruit up to 20,000 individuals eligible for annual imaging-based screening and will assess the test's performance in comparison.